Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (9558)	11/25/2003 7:49:05 PM
From: tuck	Read Replies (2) \| Respond to of 52153

Fred, Here's the PR on the approval today: Message 19537003 As you can see, my memory was a little off (to everyone's surprise, I'm sure). They have to screen patients for QTc wave prolongation; apparently they can't give a small dose first to test for allergic reaction, so they're doing a comprehensive registration and informed consent procedure. The market seems disinclined to count Plenaxis sales before they're hatched, given these little hurdles. Anyone here care to handicap the success of their launch? Cheers, Tuck